Association of ABO Blood Groups with HPV Genotypes and Cervical Lesions in HPV-Positive Women Authors: Ramazan Adan, Hicran Acar Şirinoğlu, Alpaslan Kaban, Deniz Taşdemir, Muhammet Yılmaz, Fatih Şahin, Alp Koray Kinter Published: 2026 ABSTRACT AbstractAimThis study aimed to investigate the distribution of ABO and Rh blood groups among HPV-positive women and to evaluate their associations with HPV genotype, cervical cytology, and colposcopic findings.Materials and MethodsThis retrospective observational study included 128 HPV-positive women who underwent cervical cytology and colposcopic evaluation. Patient data were retrieved from electronic medical records and classified according to ABO/Rh blood groups, HPV genotype, cervical cytology, and colposcopic findings. HPV DNA testing was performed using the cobas® 4800 HPV Test, a real-time PCR-based assay providing individual detection of HPV16 and HPV18 and pooled detection of other high-risk HPV genotypes. ABO/Rh distributions were compared with those of a historical blood-donor reference population of 123,900 individuals.ResultsAmong 128 HPV-positive women, ABO/Rh distribution was A Rh-positive 26.6%, A Rh-negative 7.0%, O Rh-positive 29.7%, O Rh-negative 8.6%, B Rh-positive 12.5%, B Rh-negative 1.6%, and AB Rh-positive 14.1%. No statistically significant associations were observed between ABO/Rh blood groups and cervical cytology, colposcopic findings, or HPV genotype. The overall ABO distribution differed significantly from that of the historical reference population (goodness-of-fit test, p=0.006). Blood group A was less frequent in the HPV-positive cohort (33.6% vs 43.8%; p=0.020), whereas AB was more frequent (14.1% vs 5.1%; p=0.005). No significant differences were observed for blood groups O and B or Rh distribution.ConclusionABO blood group distribution differed between HPV-positive women and the historical blood-donor reference population, particularly for blood groups A and AB. However, no significant associations were identified between ABO/Rh blood groups and cervical cytology, colposcopic findings, or HPV genotype. These findings should be considered preliminary and require confirmation in larger prospective studies.Keywords: HPV, cervical cancer, blood type Introduction A subset of human papillomavirus (HPV) infections is causally associated with the development of epithelial tumors and cancers. Like many pathogens, HPV initiates infection by binding to heparan sulfate proteoglycans (HSPGs) on the surface of target cells. Following this initial attachment, the virus translocates to distinct secondary receptors that mediate viral internalization. Despite extensive investigation, the mechanisms underlying HPV translocation to these secondary receptors, as well as the identity of the receptors themselves, remain incompletely understood.1 Papillomaviruses are non-enveloped, double-stranded deoxyribonucleic acid (DNA) viruses belonging to the family Papillomaviridae and the genus Papillomavirus. They exhibit a high degree of species specificity, with human papillomaviruses (HPVs) infecting only humans. To date, more than 200 HPV types have been identified and classified as either cutaneous or mucosal according to their tissue tropism. HPVs possess an approximately 8-kilobase circular double-stranded DNA genome encoding eight genes, including the two major structural capsid proteins, L1 and L2.2–4 Most HPV infections, including those caused by oncogenic genotypes, are transient and resolve spontaneously within 12 months.5,6 However, persistent infection with oncogenic HPV lasting longer than 12 months is associated with an increased risk of developing precancerous and malignant cervical lesions, although not all persistent infections progress to neoplasia.7 In the United States, the median age at diagnosis of cytologically detected cervical precancerous lesions is approximately 10 years after the median age at first sexual intercourse.8 HPV infection is associated with a broad spectrum of clinical manifestations, ranging from benign lesions to invasive malignancies. Genital warts (condyloma acuminata) are benign anogenital lesions predominantly caused by low-risk HPV types 6 and 11.9 In contrast, squamous intraepithelial lesions and carcinomas of the cervix, vagina, vulva, anus, and penis are primarily associated with high-risk HPV genotypes. Approximately 15 HPV types are classified as high-risk due to their oncogenic potential, with HPV types 16 and 18 accounting for the majority of cervical cancer cases worldwide.10 Among these, HPV16 is the most prevalent genotype and carries the highest risk of progression to cervical cancer.11 The ABO blood group system comprises four major erythrocyte phenotypes—A, B, AB, and O—determined by specific carbohydrate antigens expressed on the erythrocyte surface.12 In most populations, blood group O is the most prevalent, followed by blood groups A, B, and AB.13 Previous studies have suggested that ABO blood groups may influence susceptibility to a variety of conditions, including infectious diseases, malignancies, cardiovascular disorders, and metabolic diseases.14 More recently, associations between ABO blood groups and viral infections have also been investigated. A systematic review and meta-analysis examining ABO and Rh blood groups in Chikungunya virus infection suggested that susceptibility may vary according to blood group, while also highlighting substantial heterogeneity across studies.15 The relationship between ABO/Rh blood groups and cervical cancer has likewise been investigated for decades, yet the available evidence remains inconsistent. A recent study by Mandato et al, which reviewed previous evidence and evaluated cervical cancer patients, found no significant association between ABO blood group and survival and emphasized that the relationship between ABO/Rh status and cervical cancer remains inconclusive.16 Importantly, previous studies have predominantly focused on established cervical cancer rather than HPV infection itself, HPV genotype, or HPV-related cervical findings. Therefore, evidence specifically addressing ABO and Rh blood groups in HPV-positive women remains limited. Because the present study included exclusively HPV-positive women, it was not designed to evaluate susceptibility to HPV acquisition, but rather to investigate the distribution of ABO and Rh blood groups and their associations with HPV genotype, cervical cytology, and colposcopic findings among women with established HPV positivity. Materials and Methods This retrospective observational study included 128 HPV-positive women who presented to Prof. Dr. Cemil Taşcıoğlu City Hospital between December 2022 and December 2024, underwent cervical cytology (Pap smear) and colposcopy and histopathological results. Patient data were retrospectively retrieved from the hospital’s electronic medical records. Patients were classified according to their ABO and Rh blood groups, HPV genotype, cervical cytology (Pap smear) results, and colposcopic findings (benign or premalignant). After visualizing the cervix with a speculum on the gynecological examination table, a cervical sample was taken with a smear brush. The collected samples were sent to the laboratory for conventional Pap smear examination and HPV testing. HPV DNA testing was performed using the cobas® 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA, USA), a real-time polymerase chain reaction (PCR)-based assay. The assay provides individual detection of HPV genotypes 16 and 18 and pooled detection of other high-risk HPV genotypes. DNA extraction, amplification, and detection were performed according to the manufacturer’s instructions, and the assay’s internal controls were used to monitor sample adequacy, amplification performance, and potential PCR inhibition. For the purposes of the present study, HPV results were categorized as HPV 16/18 and other high-risk HPV genotypes. Those with HPV types 16 and 18 were directly referred for colposcopic examination. Patients with HPV positivity (types 16 and 18) were referred for colposcopic examination if abnormal findings were observed in their smear tests. Population-based ABO and Rh blood group distribution data were obtained from a previously published analysis of 123,900 blood donors in Istanbul.16 The ABO and Rh blood group distributions of the study cohort were compared with those of the historical blood-donor reference population. Ethical approval for this study was obtained from the local ethics committee at Istanbul Prof Dr Cemil Taşçıoğlu city Hospital on March 4, 2024, with protocol number 32. All patients provided informed consent, and all patients consented to the use of their medical data in scientific studies. Results A total of 128 cases were included in the study. The distribution of ABO and Rh blood groups was as follows: A Rh-positive, 34 (26.56%) and A Rh-negative, 9 (7.04%); O Rh-positive, 38 (29.68%) and O Rh-negative, 11 (8.60%); B Rh-positive, 16 (12.50%) and B Rh-negative, 2 (1.56%); and AB Rh-positive, 18 (14.06%) (Table 1). Table 1Pap smear, colposcopy, and HPV test results of 128 women classified according to blood groupsBlood GroupRH(±)SMEARpColposcopypHPVpn(%)n(%)BenignPremalignBenignPremalign16\18OtherA34(26.56)21 (30.43)13 (22.03)0.18616 (22.22)18 (32.14)0.07311 (22.92)23 (28.75)0.72143(33.60)9(7.04)4 (5.80)5 (8.47)8 (11.11)1 (1.79)3 (6.25)6 (7.50)O38(29.68)17 (24.64)21 (35.59)24 (33.33)14 (25.00)18 (37.50)20 (25.00)49(38.28)11(8.60)3 (4.35)8 (13.56)3 (4.17)8 (14.29)4 (8.33)7 (8.75)B16(12.5)10 (14.49)6 (10.17)10 (13.89)6 (10.71)7 (14.58)9 (11.25)18(14.06)2(1.56)2 (2.90)0 (0.00)2 (2.78)0 (0.00)0 (0.00)2 (2.50)AB18(14.06)12 (17.39)6 (10.17)9 (12.50)9 (16.07)5 (10.42)13 (16.25)18(14.06)0000000128 Pap smear, colposcopy, and HPV test results of 128 women classified according to blood groups When A Rh-positive and A Rh-negative individuals were analyzed together as the A blood group, the distribution of benign and premalignant cervical smear results was 21 (30.43%) and 13 (22.03%) for A Rh-positive, and 4 (5.80%) and 5 (8.47%) for A Rh-negative individuals, respectively. No significant association was observed between the A blood group and cervical smear results (p = 0.186). Regarding colposcopic findings, benign and premalignant lesions were identified in 16 (22.22%) and 18 (32.14%) A Rh-positive patients, and in 8 (11.11%) and 1 (1.79%) A Rh-negative patients, respectively. The association between the A blood group and colposcopic findings was not statistically significant (p = 0.073). For HPV genotype distribution, HPV 16/18 was detected in 11 (22.92%) A Rh-positive and 3 (6.25%) A Rh-negative patients, whereas other high-risk HPV genotypes were identified in 23 (28.75%) and 6 (7.50%) patients, respectively. There was no significant association between the A blood group and HPV genotype distribution (p = 0.721). When O Rh-positive and O Rh-negative blood groups were analyzed together as blood group O, the distribution of benign and premalignant cervical cytology was as follows: O Rh-positive, 17 (24.64%) benign and 21 (35.59%) premalignant cases; O Rh-negative, 3 (4.35%) benign and 8 (13.56%) premalignant cases. Regarding colposcopic findings, O Rh+positive cases comprised 24 (33.33%) benign and 14 (25.00%) premalignant lesions, whereas O Rh-negative cases included 3 (4.17%) benign and 8 (14.29%) premalignant lesions. For HPV genotype distribution, HPV16/18 infection was detected in 18 (37.50%) O Rh-positive and 4 (8.33%) O Rh-negative cases, while other high-risk HPV genotypes were identified in 20 (25.00%) O Rh-positive and 7 (8.75%) O Rh-negative cases. In the B blood group, the distribution of benign/premalignant smear results was 10 (14.49%) and 6 (10.17%) in Rh-positive patients, and 2 (2.90%) and 0 (0.00%) in Rh-negative patients, respectively. The distribution of benign/premalignant colposcopic findings was 10 (13.89%) and 6 (10.71%) in B Rh-positive patients, and 2 (2.78%) and 0 (0.00%) in B Rh-negative patients, respectively. Regarding HPV genotype distribution, HPV 16/18 was detected in 7 (14.58%) B Rh-positive patients, while other high-risk HPV genotypes were identified in 9 (11.25%) patients. No HPV 16/18-positive cases were observed among B Rh-negative patients, whereas other high-risk HPV genotypes were detected in 2 (2.50%) patients. In the AB blood group, the distribution of benign/premalignant smear results was 12 (17.39%) and 6 (10.17%), respectively. The distribution of benign/premalignant colposcopic findings was 9 (12.50%) and 9 (16.07%), respectively. Regarding HPV genotype distribution, HPV 16/18 was detected in 5 (10.42%) patients, while other high-risk HPV genotypes were identified in 13 (16.25%) patients. The distribution of test results and their potential associations within each ABO blood group and Rh subgroup were evaluated. Cervical cytology results were categorized as benign or premalignant, colposcopic findings as benign or premalignant, and HPV results as HPV 16/18 or other high-risk HPV genotypes. No statistically significant associations were identified between smear and colposcopy, smear and HPV genotype, or colposcopy and HPV genotype within any blood group or Rh subgroup. In the A blood group, none of the comparisons between smear and colposcopy (p = 0.359), smear and HPV genotype (p = 0.824), or colposcopy and HPV genotype (p = 0.625) reached statistical significance. Similarly, no significant associations were observed in the A Rh-negative subgroup for smear–colposcopy (p = 0.125), smear–HPV genotype (p = 1.000), or colposcopy–HPV genotype (p = 0.118) (Table 2). Table 2Distribution of test results and their potential associations within each ABO blood group and Rh subgroupBlood GroupRH(±)SmearColposcopyHPVSmear vs ColposcopySmear vs hpvColposcopy vs hpvn(%)n(%)BenignPremalignBenignPremalign16\18Other grouppppA34 (26.56)21 (30.43)13 (22.03)16 (22.22)18 (32.14)11 (22.92)23 (28.75)0.3590.8240.62543 (33.60)9 (7.03)4 (5.80)5 (8.47)8 (11.11)1 (1.79)3 (6.25)6 (7.50)0.1251.0000.118O38 (29.69)17 (24.64)21 (35.59)24 (33.33)14 (25.00)18 (37.50)20 (25.00)0.1670.6640.12549 (38.28)11 (8.59)3 (4.35)8 (13.56)3 (4.17)8 (14.29)4 (8.33)7 (8.75)1.0000.2890.503B16 (12.50)10 (14.49)6 (10.17)10 (13.89)6 (10.71)7 (14.58)9 (11.25)1.0001.0001.00018 (14.06)2 (1.56)2 (2.90)0 (0.00)2 (2.78)0 (0.00)0 (0.00)2 (2.50)--AB18 (14.06)12 (17.39)6 (10.17)9 (12.50)9 (16.07)5 (10.42)13 (16.25)0.4531.0000.21918 (14.06)0000000--128 Distribution of test results and their potential associations within each ABO blood group and Rh subgroup In the O blood group, no statistically significant associations were observed between smear and colposcopy (p = 0.167), smear and HPV genotype (p = 0.664), or colposcopy and HPV genotype (p = 0.125). Similarly, no significant associations were identified among any of the test pairs in the O Rh-negative subgroup (all p > 0.05). In the B Rh-positive subgroup, comparisons between smear and colposcopy, smear and HPV genotype, and colposcopy and HPV genotype were all statistically non-significant (all p = 1.000). Statistical analysis could not be performed in the B Rh-negative subgroup because of the very small sample size (n = 2). In the AB Rh-positive subgroup, no significant associations were found between smear and colposcopy (p = 0.453), smear and HPV genotype (p = 1.000), or colposcopy and HPV genotype (p = 0.219). No analysis was performed for the AB Rh-negative subgroup because no cases were available. Overall, no statistically significant associations were identified between cervical cytology, colposcopic findings, and HPV genotype distribution within any ABO blood group or Rh subgroup. The distribution of ABO blood groups, Rh status, and their associations with cervical cytology, colposcopic findings, and HPV genotype were evaluated in 128 HPV-positive women (Table 3). The ABO blood group distribution was A (33.6%), O (38.3%), B (14.1%), and AB (14.1%), while 106 (82.8%) patients were Rh-positive and 22 (17.2%) were Rh-negative (Table 3). Table 3Comparison of ABO blood group and Rh status distribution in 128 HPV-positive women with a reference groupHPV PositiveReference ArticleP TotalP RHRH(+)RH(-)TotalRH(+)RH(-)ToplamA34 (26.56)9 (7.03)43 (33.59)47.496 (38.33)6793 (5.48)54.289 (43.82)0.0200.104O38 (29.69)11 (8.59)49 (38.28)36.427 (29.40)5451 (4.40)41.878 (33.80)0.3040.056B16 (12.50)2 (1.56)18 (14.06)16.294 (13.15)2560 (2.07)18.854 (15.22)0.8061.000AB18 (14.06)0 (0.00)18 (14.06)7971 (6.43)908 (0.73)8879 (7.17)0.0050.248 Comparison of ABO blood group and Rh status distribution in 128 HPV-positive women with a reference group No significant associations were identified between ABO blood group and cervical cytology (p = 0.063), colposcopic findings (p = 0.767), or HPV genotype distribution (HPV 16/18 vs other high-risk genotypes; p = 0.506). Similarly, Rh status was not associated with cytological findings, colposcopic findings, or HPV genotype (all p > 0.05). Compared with the reference population, the overall ABO blood group distribution differed significantly among HPV-positive women (goodness-of-fit test, p = 0.006), primarily because of the higher-than-expected frequency of the AB blood group (14.1% vs approximately 7% in the reference population). Despite this difference, ABO blood group was not associated with clinically relevant outcomes, including cervical cytology, colposcopic findings, or HPV genotype distribution. Women infected with HPV 16/18 showed a higher proportion of premalignant colposcopic findings than those infected with other high-risk HPV genotypes (52.9% vs 38.9%). However, this difference was not statistically significant (OR = 1.76, p = 0.119), indicating that the present data do not provide sufficient evidence to support an increased risk of premalignant lesions associated with HPV 16/18 infection. The distribution of the HPV-positive cohort was compared with that of the reference population presented in Table 4 (n = 123,900) (A: 54,289; O: 41,878; B: 18,854; AB: 6,359; corresponding Rh subgroups are presented in the relevant rows) (Table 4). Table 4Distribution of the HPV-positive cohort compared to the distribution of the reference populationHPV-PositiveBlood GroupN=128 n(%)RH(±)N=128n(%)Reference ArticleReference ArticleRH (±)N=123900n (%)P TotalP RHA34(26.56)A47.496 (38.3%)0.0200.10443(33.60)9(7.04)54.289(43.8)6793 (5.5%)O38(29.68)O36.427 (29.4%)0.3040.05649(38.28)11(8.60)41.878(33.8)5451 (4.4%)B16(12.5)B16.294 (13.2%)0.8061.00018(14.06)2(1.56)18.854(15.3)2560 (2.1%)AB18(14.06)AB5451 (4.4%)0.0050.24818(14.06)0(0)6359(5.1)908 (0.7%) Distribution of the HPV-positive cohort compared to the distribution of the reference population The p(Total) values for the comparison were 0.020 for blood group A, 0.304 for O, 0.806 for B, and <0.001 for AB. The p(Rh) values for the Rh-positive/Rh-negative distribution within each ABO blood group were 0.104 for A, 0.056 for O, 1.000 for B, and 0.096 for AB. This analysis evaluated whether the ABO blood group distribution in the HPV-positive cohort differed from that of the reference population and whether the Rh-positive/Rh-negative distribution within each ABO blood group also differed. The frequency of blood group A was significantly higher in the HPV-positive cohort than in the reference population (p = 0.020), whereas the frequency of blood group AB was markedly higher (p < 0.001). In contrast, no significant differences were observed for blood groups O (p = 0.304) or B (p = 0.806). Within each ABO blood group, the distribution of Rh-positive and Rh-negative individuals did not differ significantly from that of the reference population (A, p = 0.104; O, p = 0.056; B, p = 1.000; AB, p = 0.096), indicating that the observed differences were primarily attributable to the ABO blood group distribution rather than Rh status. These findings indicate an overrepresentation of the AB blood group, and to a lesser extent the A blood group, among HPV-positive women compared with the reference population. However, the results should be interpreted with caution. Because multiple statistical comparisons were performed, the possibility of type I error cannot be excluded. Furthermore, the comparison with the reference population did not account for potential confounding factors, including age, geographic variation, and referral-center characteristics. Therefore, these findings should not be interpreted as evidence of a causal association. The prevalence of premalignant colposcopic findings was 52.9% (27/51) in the HPV16/18-positive group and 38.9% (30/77) in the group positive for other high-risk HPV genotypes. The estimated odds ratio was 1.76, indicating that the odds of detecting a premalignant colposcopic lesion were 1.76-fold higher in women with HPV16/18 infection than in those infected with other HPV types. However, this difference did not reach statistical significance (χ2-test, p = 0.119) (Table 5). Table 5Prevalence of premalignant colposcopic findings in the HPV16/18-positive group and other HPV genotypesColposcopyBenignColposcopyPremalignTotalPremalignantTransformation Rate (%)Hpv16/18 +242751% 52.9Hpv other +473077% 38.9Total7157128% 44.5 Prevalence of premalignant colposcopic findings in the HPV16/18-positive group and other HPV genotypes Accordingly, no statistically significant association between HPV16/18 positivity and premalignant colposcopic findings could be demonstrated in the present cohort. Therefore, these results should not be interpreted as definitive evidence that HPV16/18 infection increases the risk of premalignant transformation. Rather, the findings suggest a trend toward a higher prevalence of premalignant lesions among HPV16/18-positive women, although the available evidence was insufficient to confirm this association statistically. The lack of statistical significance is likely attributable to the relatively limited sample size and the moderate magnitude of the observed effect. Discussion In the present study, the prevalence of premalignant colposcopic lesions was higher among women with HPV16/18 infection than among those infected with other high-risk HPV genotypes (52.9% vs 38.9%). However, this difference did not reach statistical significance (OR = 1.76, p = 0.119). Although HPV16/18 infection is well established as the genotype with the highest oncogenic potential, the absence of a statistically significant association in our study may be explained by the duration of HPV exposure. Most patients included in the present cohort were newly diagnosed with HPV infection, suggesting that the duration of viral persistence was relatively short. Persistent HPV infection, rather than the presence of HPV alone, is recognized as one of the principal determinants of progression to cervical intraepithelial neoplasia and invasive cervical cancer.5,6 Therefore, the lack of significant associations among HPV genotype, cervical cytology, and colposcopic findings may be attributable to the relatively short and unmeasured duration of HPV infection in our study population. Comparison of the HPV-positive cohort with the reference population demonstrated a significant difference in the overall ABO blood group distribution (goodness-of-fit test, p = 0.006). This difference was primarily driven by the higher-than-expected frequency of the AB blood group among HPV-positive women, whereas no significant difference was observed in the Rh blood group distribution (Table 3). When individual blood groups were analyzed separately, the frequency of blood group A was significantly higher than that of the reference population (p = 0.020), while the AB blood group showed an even stronger association (p < 0.001). In contrast, no significant differences were observed for blood groups O (p = 0.304) or B (p = 0.806) (Table 4). These findings suggest that susceptibility to HPV infection may vary according to ABO blood group, although larger prospective studies are required to confirm this observation. A comprehensive systematic review and meta-analysis published by Cui et al in 2023 demonstrated that ABO blood groups are associated with susceptibility to several human malignancies.17 However, that study evaluated the relationship between ABO blood groups and cancer risk in general and did not specifically investigate HPV infection or HPV genotype distribution. In contrast, the primary objective of the present study was to explore the association between ABO blood groups and HPV infection. To the best of our knowledge, this is among the first studies to simultaneously evaluate ABO and Rh blood groups, HPV genotype, cervical cytology, and colposcopic findings within the same HPV-positive cohort. One of the most noteworthy findings of our study was the significantly increased frequency of the AB blood group among HPV-positive women. This observation may have a plausible biological explanation. Initial attachment of HPV to epithelial cells is mediated by heparan sulfate proteoglycans (HSPGs), which function as primary attachment receptors. Following this initial interaction, the virus undergoes conformational changes and is transferred to secondary receptors that mediate viral internalization. Although the identity and molecular mechanisms of these secondary receptors have not yet been fully elucidated,1 ABO blood group antigens may represent potential candidate molecules involved in this process. ABO antigens are highly expressed carbohydrate structures on epithelial surfaces. Individuals with the AB blood group simultaneously express both A and B antigens, resulting in a more complex glycosylation pattern than that observed in the other blood groups. We hypothesize that this enriched glycan microenvironment may facilitate HPV attachment or transfer to secondary receptors, thereby increasing susceptibility to HPV infection. Although this hypothesis remains speculative and requires experimental validation, our findings provide indirect epidemiological evidence supporting a possible role of ABO antigens in HPV-host interactions. Interestingly, in our previous study evaluating the relationship between ABO blood groups and gynecological malignancies, cervical cancer was also found to occur significantly more frequently among women with the AB blood group.18 The consistency between the findings of the present study and our previous observations raises the possibility of a relationship between ABO blood group distribution and HPV-related cervical disease. Nevertheless, this observation should be considered hypothesis-generating and requires confirmation in appropriately controlled prospective studies. Similar observations have been reported for other viral infections. During the COVID-19 pandemic, several studies demonstrated that individuals with blood groups A and AB had a higher susceptibility to SARS-CoV-2 infection and severe disease, whereas individuals with blood group O appeared to have a lower risk.19 These findings suggest that ABO blood group antigens may influence host-virus interactions beyond erythrocytes, potentially affecting viral attachment to epithelial cells. Whether a similar mechanism contributes to HPV infection remains to be determined. The clinical implication of our findings is that ABO blood group may represent a readily available biomarker for identifying individuals with increased susceptibility to HPV infection. If confirmed in larger multicenter studies, women with the AB blood group may warrant closer surveillance within HPV screening programs. However, these findings should currently be considered hypothesis-generating rather than practice-changing. Despite the remarkable reduction in cervical cancer mortality following the widespread implementation of cervical cytology screening, cervical cancer remains an important cause of cancer-related morbidity and mortality among women worldwide. According to the World Health Organization, approximately 604,000 new cases and 342,000 cervical cancer-related deaths occurred globally in 2020.20,21 Recent experimental studies have also highlighted the complexity of the molecular pathways involved in cervical cancer progression and the potential for novel therapeutic approaches. Mondal et al demonstrated that modulation of p53 and ERK2/MAPK signaling, together with oxidative and endoplasmic reticulum stress pathways, was associated with reduced proliferation and migration of cervical cancer cells following treatment with triazole-chelated iridium(III) complexes.22 These findings illustrate the growing interest in molecular mechanisms and potential therapeutic targets involved in cervical carcinogenesis. Therefore, identification of biological factors associated with HPV-related cervical disease and cervical carcinogenesis remains an important research priority. Associations between ABO blood groups and several malignancies, including gastric, pancreatic, and colorectal cancers, have previously been reported.23,24 Our findings suggest that HPV infection may also exhibit variation according to ABO blood group, particularly among women with the AB phenotype. However, further epidemiological and molecular studies are necessary before definitive conclusions can be drawn. The principal limitations of the present study include its retrospective, single-center design and relatively small sample size, particularly within some Rh-negative subgroups, which may have limited the statistical power to detect modest associations. The use of a historical blood-donor reference population rather than a contemporaneous HPV-negative control group may have introduced selection bias and limits the ability to draw conclusions regarding susceptibility to HPV infection. In addition, potentially relevant confounding factors, including smoking, HPV vaccination status, previous cervical disease, and immunosuppression, were not available for adjustment. The duration of HPV infection could not be determined, and advanced molecular analyses were not performed. Furthermore, multiple subgroup comparisons were conducted without adjustment for multiple testing, increasing the possibility of type I error. Therefore, the observed findings should be interpreted cautiously and regarded as exploratory and hypothesis-generating. Nevertheless, an important strength of this study is the simultaneous evaluation of ABO and Rh blood groups, HPV genotype, cervical cytology, and colposcopic findings within the same HPV-positive cohort, an area for which evidence remains limited. Conclusion This study demonstrated differences in the distribution of ABO blood groups between HPV-positive women and a historical blood-donor reference population; these differences were primarily characterized by a higher frequency of blood group A, and particularly blood group AB, while no significant differences were observed for blood groups O and B. No significant difference in Rh distribution was detected compared with the reference population. Furthermore, within the HPV-positive cohort, ABO and Rh blood groups were not significantly associated with HPV genotype, cervical cytology, or colposcopic findings. Since the study included only HPV-positive women and used a historical blood-donor population for comparison, these findings should not be interpreted as evidence that ABO blood groups influence susceptibility to HPV infection or HPV acquisition. Rather, the observed differences in ABO blood group distribution should be regarded as preliminary and hypothesis-generating. Larger, well-controlled, multicenter prospective studies incorporating appropriate HPV-negative comparison groups are needed to confirm these observations and to clarify whether ABO blood group antigens have any biological relevance to HPV-related cervical disease. Disclosure The authors report no conflicts of interest in this work. References